Monoclonal Antibodies
Sapanisertib + Bevacizumab for Glioblastoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying the side effects and best dose of the TORC1/2 inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma or other solid tumors.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Popular Filters
Trials for Ovarian Cancer Patients
Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
mTORC1/2 Inhibitor
mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of two different drug combinations in treating patients with recurrent endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer.
Trials for SOC Patients
Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
mTORC1/2 Inhibitor
mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of two different drug combinations in treating patients with recurrent endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer.
Trials for Metastatic Patients
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
mTOR inhibitor
Everolimus + Letrozole +/- Ribociclib for Endometrial Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial is testing a new drug combination for advanced or recurrent endometrial cancer. It targets patients whose cancer has spread or returned. The treatment works by blocking enzymes needed for cancer cell growth and by stopping the cells from dividing or spreading. Anlotinib is a new drug that targets multiple aspects of cancer growth.
Trials for HER2 Positive Patients
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Tyrosine Kinase Inhibitor
Afatinib for Uterine Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing Afatinib, a drug used to treat other types of cancer, to see if it is effective in treating uterine serous carcinoma, a type of uterine cancer. The objectives are to see if the drug extends progression-free survival, overall survival, and has a good safety profile.
Enzyme Inhibitor
Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors
Recruiting1 awardPhase 1
Los Angeles, California
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Chemotherapy
Herceptin Hylecta or Phesgo + Chemotherapy for Uterine Cancer
Recruiting1 awardPhase 2 & 3
Ames, Iowa
This trial is testing whether adding Herceptin Hylecta or Phesgo to usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Phase 3 Trials
Chemotherapy
Herceptin Hylecta or Phesgo + Chemotherapy for Uterine Cancer
Recruiting1 awardPhase 2 & 3
Ames, Iowa
This trial is testing whether adding Herceptin Hylecta or Phesgo to usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Trials With No Placebo
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.